Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
WillisMDRobertsonNP.Alemtuzumab for multiple sclerosis. Curr Neurol Neurosci Rep2016; 16(9): 84.
2.
ColesA.Alemtuzumab treatment of multiple sclerosis. Semin Neurol2013; 33(1): 66–73.
3.
WillisMDHardingKEPickersgillTPet al. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler2016; 22(9): 1215–1213.
4.
SaarelaMSenthilKJonesJet al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology2018; 90(18): 849–851.
ThachilJJadhavVGautamMet al. The development of sarcoidosis with the use of alemtuzumab – Clues to T-cell immune reconstitution. Br J Haematol2007; 138(4): 559–560.
7.
Peixoto de MirandaÉJMunhoz LeiteOHSeixas DuarteMI.Immune reconstitution inflammatory syndrome associated with pulmonary sarcoidosis in an HIV-infected patient: An immunohistochemical study. Braz J Infect Dis2011; 15(6): 601–606.
8.
GelfandJMCotterJKlingmanJet al. Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. Neurol Neuroimmunol Neuroinflamm2014; 1(3): e34.
